Abstract
We have measured the plasma levels of somatomedin‐C (SM‐C) or insulin‐like growth factor I (IGF‐I) in 13 patients with progressive systemic sclerosis (PSS) and age and sex matched healthy controls. We found the plasma SM‐C levels to be within normal limits in all the patients. Thus, if somatomedin‐C plays a role in the pathogenesis of PSS, it is more likely to be at the fibroblast receptor level or in the synthetic response of fibroblasts to SM‐C.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 639-642 |
| Number of pages | 4 |
| Journal | British Journal of Dermatology |
| Volume | 119 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 1988 |
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'Plasma somatomedin‐C levels in systemic sclerosis'. Together they form a unique fingerprint.
Cite this
ROTHE, M. J., ALTMAN, R. D., & FALANGA, V. (1988). Plasma somatomedin‐C levels in systemic sclerosis. British Journal of Dermatology, 119(5), 639-642. https://doi.org/10.1111/j.1365-2133.1988.tb03476.x